MIT Sloan BioInnovations Conference March 12, 2010
Boston Marriott Cambridge Hotel
Kendall Square, Cambridge MA


Please check back as panelist information is continually being updated!

Bringing Innovation to Market

In the face of limited access to venture capital, the flow of commercialized innovations has slowed to a trickle, but we hear time and again that the best ideas can still get funding.  What differentiates these innovations in the early-stage capital markets?  What development challenges and opportunities arise from the limited availability of capital?  How are bigger firms thinking strategically about capturing value and bringing these innovations to market?.


Christian Cortis
Principal, Advanced Technology Ventures

Daniel Curran
VP, Corporate Development, Millennium Pharmaceuticals

Rahul K. Dhanda
Director, Strategic Marketing, T2 Biosystems

Bernadette (Bonnie) Fendrock
President and CEO, Hepregen Corporation


Jonathan Hodgson
Senior Manager, L.E.K. Consulting

Panel Lead

Stephane Shu-Kin-So, MBA 2011

Emerging Markets: The future of Pharma growth?

Traditional markets for pharma/biotech and medical device manufacturers (US, EU-5, Japan) are facing decreasing rates of profit growth due to pending patent expirations and increased regulatory and reimbursement pressures.  The industry is now looking to emerging markets for a brighter future.  This panel will examine  whether the industry’s optimism related to emerging markets is justified and attempt to assess the true potential of these markets – what are the encouraging signs that form the basis for this optimism and what challenges lie ahead to turn their vision for these markets into reality.


Jonathan Fleming
Managing General Partner, Oxford Bioscience Partners

James Geraghty
Senior Vice President, Genzyme Corporation

Ben Rymzo
Principal, Frankel Group

Scott Stern
Carole Levy Professor of Management and Strategy, Kellogg School of Management


Steve Rosen
Partner, Simon-Kucher & Partners

Panel Lead

Kanaka Pattabiraman, MBA 2011

Beyond Electronic Medical Records:

In addition to the $44B expected to be allocated towards EMRs, an additional $2B is slated to help build a "health information network" in the US. What will this mean for the state of the connected health movement? What impact will this have on communication and collaboration in global healthcare?


Jonathan Bush
Chairman and CEO, athenahealth, Inc

Glen Comiso
Director, Massachusetts Technology Collaborative

Clifford Goldsmith, MD
Health Plan Solutions Strategist, Microsoft Corporation

Daniel Palestrant, MD
Founder and CEO, Sermo, Inc


Ashish Jha, MD, MPH
Associate Professor, Harvard School of Public Health

Panel Lead

Karan Singh, MBA 2011

Healthcare Reform in Limbo: Is there still an imperative for change?

Is there still an imperative for change? This panel will elucidate both sides of the current debate. We will explore the relationship between cost and quality. Is the health care system delivering value for our money? The panel discussion will include lessons learned from universal coverage in Massachusetts. In a new era of cost containment, we will discuss something close to the heart of MIT: Innovation.


Gary Gottlieb, MD, MBA
President and CEO of Partners HealthCare System, Inc.

Louis Kuchnir, MD, PhD
Founding Physician, Kuchnir Dermatology & Dermatologic Surgery

Brad Prosek
Senior Director, Cubist Pharmaceuticals, Inc.

Meredith Rosenthal, PhD
Associate Professor, Harvard School of Public Health


Brian Carey, Esquire
Partner, Foley Hoag

Panel Lead

Tina Jovic, MBA 2011